{
  "docId": "019de072-f0cb-7745-907c-f9e6b87d2817",
  "docSlug": "e5afd111c5ca3d26ccce5d5b91b81d60",
  "documentTitle": "BioNTech | Investor Day Presentation Deck | 156 slides",
  "authorId": "biontech",
  "authorName": "BioNTech",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-06-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 117,
  "pageCount": 120,
  "prevPage": 116,
  "nextPage": 118,
  "slideType": "roadmap",
  "function": "plan_implementation",
  "density": "dense",
  "nDataPoints": 2,
  "notes": "The slide uses a process flow diagram to illustrate the transition from Phase 1 to Phase 2a.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de072-f0cb-7745-907c-f9e6b87d2817/117",
  "deckHref": "/decks/019de072-f0cb-7745-907c-f9e6b87d2817",
  "deckJsonHref": "/decks/019de072-f0cb-7745-907c-f9e6b87d2817.json",
  "deckAnchorHref": "/decks/019de072-f0cb-7745-907c-f9e6b87d2817#slide-117",
  "components": [
    {
      "bbox": {
        "h": 0.4,
        "w": 0.92,
        "x": 0.04,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Phase 1 to Phase 2a trial flow",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "76ba12fc-ca4a-4afa-b801-fba79cf074c6",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.04,
        "y": 0.9
      },
      "kind": "disclaimer",
      "text": "BNT311 (Gen1046) is partnered with Genmab based on 50/50 sharing of costs and profits. CC, cervical cancer; EC, endometrial cancer; HNSCC, head and neck squamous-cell cancer; MTD, maximum tolerated dose; NSCLC, non-small-cell lung cancer, PD, progressive disease; RP2D, recommended Phase 2 dose; TNBC, triple-negative breast cancer; UC, urothelial cancer; NCT03917381.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "f8089074-c7e4-4eac-a060-b6a5bc0e103e",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.45,
        "x": 0.04,
        "y": 0.65
      },
      "kind": "list",
      "text": "Key endpoints: Primary MTD, RP2D; Safety, PK, immunogenicity; PD and biomarkers; Antitumor activity",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "4d6a0949-5e7e-4eef-917a-fe9fc4e0bb55",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.55,
        "y": 0.65
      },
      "kind": "list",
      "text": "Status: Recruiting, 11 expansion cohorts, Collaboration with Genmab",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "6c951178-8d74-4fc4-b9a7-2983db90e3f3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.08,
        "w": 0.9,
        "x": 0.04,
        "y": 0.05
      },
      "kind": "title",
      "text": "BNT311 First-in-human Phase 1/2 trial in heavily pretreated advanced solid tumors",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "12a22255-70c6-47ee-bd66-d85df7f58e3b",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "12035c0f-e4bb-4667-aceb-1ba5cb5b7689",
      "evidence": "The slide uses a linear flow diagram to show the progression of a clinical trial.",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 120,
      "from": 91,
      "beatId": "bf198718-eb7f-470f-aca0-0f710fbb4f37",
      "arcName": "The Sequoia Pitch",
      "arcSlug": "sequoia-pitch",
      "beatName": "Product Pipeline",
      "beatSlug": "sequoia-pitch-product",
      "evidence": "The presentation showcases BioNTech's product pipeline, including its oncology and infectious disease programs",
      "position": 3,
      "confidence": 0.8,
      "parentBeatName": "Evidence",
      "parentBeatSlug": "evidence"
    }
  ],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}